Difference between revisions of "Part:BBa K4165154"

 
Line 5: Line 5:
 
Tau binding peptide targeting the PHF seed of Tau
 
Tau binding peptide targeting the PHF seed of Tau
  
−
<!-- Add more about the biology of this part here
 
 
===Usage and Biology===
 
===Usage and Biology===
 +
 +
The amino acid sequence of the MM3 peptide is DPLKARHTSVWY. It is the L-enantiomeric peptide of MMD3 (BBa_K4165141). Its charge is +1, hydrophobicity is 41 %, molecular weight is 1472.65 Da. MM3 can reduce aggregates of full-length tau when mixed in ratio 1:10 and 1:5 and PHF* (VQIINK) but not PHF (VQIVYK).
  
 
<!-- -->
 
<!-- -->
 
<span class='h3bb'>Sequence and Features</span>
 
<span class='h3bb'>Sequence and Features</span>
 
<partinfo>BBa_K4165154 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K4165154 SequenceAndFeatures</partinfo>
 +
 +
 +
 +
 +
===Dry Lab===
 +
 +
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 +
MM3 is modeled by Apptest, ITASSER and TrRosetta, best model obtained from trrosetta.
 +
 +
 +
 +
 +
<html>
 +
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm3.png" style="margin-left:200px;" alt="" width="300" /></p>
 +
</html>
 +
 +
                            Figure 1.: Predicted 3D structure of Synthetic peptide MM3.
 +
 +
 +
 +
<p style=" font-weight: bold; font-size:13px;"> Table 1: Quality assessment parameters of MM3 model. </p>
 +
 +
<html>
 +
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm3-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
 +
</html>
 +
 +
 +
===References===
 +
1. Malhis, M. (2021). Selection and characterization of D-enantiomeric peptides for the investigation of options for therapy and diagnosis of Alzheimer's disease . University of Bayreuth (Germany).
  
  

Revision as of 17:48, 5 October 2022


MM3

Tau binding peptide targeting the PHF seed of Tau

Usage and Biology

The amino acid sequence of the MM3 peptide is DPLKARHTSVWY. It is the L-enantiomeric peptide of MMD3 (BBa_K4165141). Its charge is +1, hydrophobicity is 41 %, molecular weight is 1472.65 Da. MM3 can reduce aggregates of full-length tau when mixed in ratio 1:10 and 1:5 and PHF* (VQIINK) but not PHF (VQIVYK).

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]



Dry Lab

Modeling

MM3 is modeled by Apptest, ITASSER and TrRosetta, best model obtained from trrosetta. 



                            Figure 1.: Predicted 3D structure of Synthetic peptide MM3.


Table 1: Quality assessment parameters of MM3 model.


References

1. Malhis, M. (2021). Selection and characterization of D-enantiomeric peptides for the investigation of options for therapy and diagnosis of Alzheimer's disease . University of Bayreuth (Germany).